Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: A prospective, randomised, multicentre study

M. Tamm, T. Todisco, C. Feldman, J. Garbino, F. Blasi, P. Hogan, P. J. de Caprariis, I. M. Hoepelman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This study compared patients with moderate-to-severe community-acquired pneumonia (CAP) requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin, followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and bacteriological outcomes were evaluated at the end of therapy (EOT; day 12-16) or at the end of study (EOS; day 28-35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with >50% of patients classified as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success rates (cure or improvement) in the modified intent-to-treat (MITT) population at EOT were 84.3% in the ceftriaxone/azithromycin group and 82.7% in the ceftriaxone/clarithromycin or erythromycin group. At EOS, MITT success rates (cure only) were 81.7% and 75.0%, respectively. Equivalent success rates in the clinically evaluable population were 83% and 87%, respectively, at EOT, and 79% and 78%, respectively, at EOS. MITT bacteriological eradication rates were 73.2% and 67.4%, respectively, at EOT, and 68.3% vs. 60.9%, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6days, and the mean duration of therapy was 9.5 and 10.5days, respectively. The incidence of infusion-related adverse events was 16.3% and 25.2% (p 0.04), respectively. An intravenous-to-oral regimen of ceftriaxone/azithromycin was at least equivalent in efficacy and safety to the comparator regimen and appeared to be a suitable treatment option for hospitalised patients with CAP.

Original languageEnglish
Pages (from-to)162-171
Number of pages10
JournalClinical Microbiology and Infection
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Azithromycin
Clarithromycin
Ceftriaxone
Erythromycin
Multicenter Studies
Pneumonia
Length of Stay
APACHE
Therapeutics
Population
Hospitalization
Safety
Incidence

Keywords

  • Azithromycin
  • Ceftriaxone
  • Clarithromycin
  • Community-acquired pneumonia
  • Erythromycin
  • Therapy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin : A prospective, randomised, multicentre study. / Tamm, M.; Todisco, T.; Feldman, C.; Garbino, J.; Blasi, F.; Hogan, P.; de Caprariis, P. J.; Hoepelman, I. M.

In: Clinical Microbiology and Infection, Vol. 13, No. 2, 02.2007, p. 162-171.

Research output: Contribution to journalArticle

@article{9ab43d7f36ef49b483358a71c4efa690,
title = "Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: A prospective, randomised, multicentre study",
abstract = "This study compared patients with moderate-to-severe community-acquired pneumonia (CAP) requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin, followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and bacteriological outcomes were evaluated at the end of therapy (EOT; day 12-16) or at the end of study (EOS; day 28-35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with >50{\%} of patients classified as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success rates (cure or improvement) in the modified intent-to-treat (MITT) population at EOT were 84.3{\%} in the ceftriaxone/azithromycin group and 82.7{\%} in the ceftriaxone/clarithromycin or erythromycin group. At EOS, MITT success rates (cure only) were 81.7{\%} and 75.0{\%}, respectively. Equivalent success rates in the clinically evaluable population were 83{\%} and 87{\%}, respectively, at EOT, and 79{\%} and 78{\%}, respectively, at EOS. MITT bacteriological eradication rates were 73.2{\%} and 67.4{\%}, respectively, at EOT, and 68.3{\%} vs. 60.9{\%}, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6days, and the mean duration of therapy was 9.5 and 10.5days, respectively. The incidence of infusion-related adverse events was 16.3{\%} and 25.2{\%} (p 0.04), respectively. An intravenous-to-oral regimen of ceftriaxone/azithromycin was at least equivalent in efficacy and safety to the comparator regimen and appeared to be a suitable treatment option for hospitalised patients with CAP.",
keywords = "Azithromycin, Ceftriaxone, Clarithromycin, Community-acquired pneumonia, Erythromycin, Therapy",
author = "M. Tamm and T. Todisco and C. Feldman and J. Garbino and F. Blasi and P. Hogan and {de Caprariis}, {P. J.} and Hoepelman, {I. M.}",
year = "2007",
month = "2",
doi = "10.1111/j.1469-0691.2006.01633.x",
language = "English",
volume = "13",
pages = "162--171",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin

T2 - A prospective, randomised, multicentre study

AU - Tamm, M.

AU - Todisco, T.

AU - Feldman, C.

AU - Garbino, J.

AU - Blasi, F.

AU - Hogan, P.

AU - de Caprariis, P. J.

AU - Hoepelman, I. M.

PY - 2007/2

Y1 - 2007/2

N2 - This study compared patients with moderate-to-severe community-acquired pneumonia (CAP) requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin, followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and bacteriological outcomes were evaluated at the end of therapy (EOT; day 12-16) or at the end of study (EOS; day 28-35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with >50% of patients classified as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success rates (cure or improvement) in the modified intent-to-treat (MITT) population at EOT were 84.3% in the ceftriaxone/azithromycin group and 82.7% in the ceftriaxone/clarithromycin or erythromycin group. At EOS, MITT success rates (cure only) were 81.7% and 75.0%, respectively. Equivalent success rates in the clinically evaluable population were 83% and 87%, respectively, at EOT, and 79% and 78%, respectively, at EOS. MITT bacteriological eradication rates were 73.2% and 67.4%, respectively, at EOT, and 68.3% vs. 60.9%, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6days, and the mean duration of therapy was 9.5 and 10.5days, respectively. The incidence of infusion-related adverse events was 16.3% and 25.2% (p 0.04), respectively. An intravenous-to-oral regimen of ceftriaxone/azithromycin was at least equivalent in efficacy and safety to the comparator regimen and appeared to be a suitable treatment option for hospitalised patients with CAP.

AB - This study compared patients with moderate-to-severe community-acquired pneumonia (CAP) requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin, followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and bacteriological outcomes were evaluated at the end of therapy (EOT; day 12-16) or at the end of study (EOS; day 28-35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with >50% of patients classified as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success rates (cure or improvement) in the modified intent-to-treat (MITT) population at EOT were 84.3% in the ceftriaxone/azithromycin group and 82.7% in the ceftriaxone/clarithromycin or erythromycin group. At EOS, MITT success rates (cure only) were 81.7% and 75.0%, respectively. Equivalent success rates in the clinically evaluable population were 83% and 87%, respectively, at EOT, and 79% and 78%, respectively, at EOS. MITT bacteriological eradication rates were 73.2% and 67.4%, respectively, at EOT, and 68.3% vs. 60.9%, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6days, and the mean duration of therapy was 9.5 and 10.5days, respectively. The incidence of infusion-related adverse events was 16.3% and 25.2% (p 0.04), respectively. An intravenous-to-oral regimen of ceftriaxone/azithromycin was at least equivalent in efficacy and safety to the comparator regimen and appeared to be a suitable treatment option for hospitalised patients with CAP.

KW - Azithromycin

KW - Ceftriaxone

KW - Clarithromycin

KW - Community-acquired pneumonia

KW - Erythromycin

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33846307019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846307019&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2006.01633.x

DO - 10.1111/j.1469-0691.2006.01633.x

M3 - Article

C2 - 17328728

AN - SCOPUS:33846307019

VL - 13

SP - 162

EP - 171

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 2

ER -